FIELD: chemical-pharmaceutical industry, biochemistry, medicine.
SUBSTANCE: invention relates to a liposome directly effecting on αvβ3-integrin receptors and comprising cationic amphiphilic substance including 1,2-dioleoyloxy-3-(N,N,N-trimethylammonium)propane chloride, neutral lipid, lipid with a direct effect having domain with a direct effect and hydrophobic domain bound with domain of a direct effect, and nucleic acid forming complex with cationic lipid. Cationic lipid presents in the amount from about 1 to about 50 molar % and indicated lipid with a direct effect presents in the amount from about 1 to about 20 molar % wherein molar percents are calculated as measured for the total number of lipid moles in liposome. Domain with a direct effect comprises a nonpeptide antagonist of αvβ3-integrin comprising 4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethyloxy]-benzoyl-2-(S)-aminoethylsulfonamino-β-alanine (compound 10) bound covalently with hydrophilic domain by amide bond. Also, invention relates to a method for inhibition of angiogenesis and involving administration to a patient needing in inhibition of angiogenesis a liposome in the therapeutically effective dose that directly effects on αvβ3-integrin receptors and comprising nucleic acid that is able to express a protein or peptide suppressing angiogenesis.
EFFECT: valuable properties of system.
27 cl, 2 tbl, 18 dwg, 8 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS FOR USING IT | 2006 |
|
RU2448703C2 |
POLYPEPTIDES DERIVED FROM TRYPTOPHANYL-TRNA-SYNTHETASE AND USES THEREOF IN CONTROLLING OF VASCULARISATION | 2002 |
|
RU2297425C2 |
INTERFERON PRODRUG FOR CANCER TREATMENT | 2018 |
|
RU2788736C2 |
PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 | 2008 |
|
RU2488592C2 |
CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
MONOCLONAL ANTIBODY AND HYBRIDOMA AT CC HB 12382 AND METHOD FOR TREATING THE CASES OF ACUTE LUNG INJURY AND METHOD FOR TREATING THE CASES OF FIBROSIS | 1998 |
|
RU2221589C2 |
TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
METHODS AND COMPOSITIONS APPLICABLE FOR MODULATION OF ANTIOGENESIS USING PROTEIN KINASES RAF AND RAS | 2000 |
|
RU2257911C2 |
Authors
Dates
2007-02-27—Published
2002-05-30—Filed